Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 122 (2) , 365-370
- https://doi.org/10.1067/mtc.2001.114938
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Role of Endogenous Endothelin in Chronic Heart FailureCirculation, 1997
- Clinical significance of endothelin in cardiovascular diseaseCurrent Opinion in Cardiology, 1997
- Cardiopulmonary bypass and circulatory arrest increase endothelin-1 production and receptor expression in the lungThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Concomitant Endothelin Receptor Subtype-A Blockade During the Progression of Pacing-Induced Congestive Heart Failure in RabbitsCirculation, 1997
- The endothelin system and its potential as a therapeutic target in cardiovascular diseasePharmacology & Therapeutics, 1996
- Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).Circulation, 1994
- Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertensionThe Journal of Pediatrics, 1993
- Release of vasoactive substances during cardiopulmonary bypassThe Annals of Thoracic Surgery, 1992
- Circulating and Tissue Endothelin Immunoreactivity in Advanced AtherosclerosisNew England Journal of Medicine, 1991
- Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.Proceedings of the National Academy of Sciences, 1988